Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cannabix TechnologiesSTU:8CT -2.54%28 Equity-to-Asset is 0.86 as of Jan. 2026, which is 12% below its 10-year median of 0.98. GuruFocus rates STU:8CT with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Cannabix Technologies ranks better than 77.35% on this metric.
The historical rank and industry rank for Cannabix Technologies's Equity-to-Asset or its related term are showing as below:
STU:8CT'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.81 Med: 0.98 Max: 0.99
Current: 0.81
During the past 13 years, the highest Equity to Asset Ratio of Cannabix Technologies was 0.99. The lowest was 0.81. And the median was 0.98.
STU:8CT's Equity-to-Asset is ranked better than 77.35% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs STU:8CT: 0.81
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cannabix Technologies Equity-to-Asset Related Terms
Cannabix Technologies Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Cannabix Technologies's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:8CT vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Cannabix Technologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannabix Technologies Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cannabix Technologies's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cannabix Technologies's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cannabix Technologies's Equity to Asset Ratio for the fiscal year that ended in Apr. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannabix Technologies (STU:8CT) has a Equity-to-Asset of 0.86 as of Jan. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cannabix Technologies and its competitors. This is 12% below median its historical median of 0.98. Over the past decade, Cannabix Technologies' Equity-to-Asset has ranged from 0.81 to 0.99. According to the industry distribution chart, Cannabix Technologies ranks #193 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 22.7%.
Is Cannabix Technologies' Equity-to-Asset too high?
Cannabix Technologies' current Equity-to-Asset of 0.86 is 12% below median its 10-year median of 0.98. Over the past 10 years, this metric has ranged from a low of 0.81 to a high of 0.99. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Cannabix Technologies' value of 0.86 is 34.4% above this industry median. Based on the distribution chart, Cannabix Technologies ranks #193 out of 852 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Cannabix Technologies has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Cannabix Technologies' Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cannabix Technologies ranks #193 out of 852 companies for Equity-to-Asset. This places Cannabix Technologies in the top 23% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.64. Cannabix Technologies' value of 0.86 is 34.4% above this benchmark. Historically, Cannabix Technologies' own Equity-to-Asset has ranged from 0.81 to 0.99 over the past decade. While the company's 10-year median is 0.98 vs. the industry median of 0.64, Cannabix Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannabix Technologies's current Equity-to-Asset of 0.86 is 34.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cannabix Technologies and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannabix Technologies's current Equity-to-Asset is 0.86, which is 12% below median its own 10-year median of 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabix Technologies stock overvalued right now?
Cannabix Technologies (STU:8CT) has a current Equity-to-Asset of 0.86. The current Equity-to-Asset is 0.86, which is 12% below median its 10-year median of 0.98 and 34.4% above the Medical Devices & Instruments industry median of 0.64. Cannabix Technologies' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cannabix Technologies (STU:8CT), the current Equity-to-Asset is 0.86 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cannabix Technologies Inc is engaged in the development of marijuana and alcohol breath testing technologies. Its products are Cannabix Marijuana Breath Test and BreathLogix Alcohol Breathalyzer.
28GF Score
Get the complete analysis for STU:8CT
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:8CT has been successfully added to your 
